Identification of the Soybean Hull Allergens Responsible for the Barcelona Asthma OutbreaksCodina R.a · Lockey R.F.a · Fernández-Caldas E.b · Rama R.c
aDivision of Allergy and Immunology, Department of Internal Medicine, University of South Florida and James A. Haley VA Hospital, Tampa, Fla. , USA; bCBF LETI, Madrid, and cPhysiology Department, College of Biology, University of Barcelona, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Soybean hulls were identified as the etiologic agent responsible for the asthma outbreaks that occurred in Barcelona and Cartagena, Spain. Objective: To identify the main soybean hull allergens using the sera of 18 asthmatic epidemic patients from Barcelona and to compare the results to those previously reported. Methods: Specific IgE to a soybean hull allergen extract was determined by radioimmunoassay and by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) in a 10–20% Tris–tricine gradient gel followed by Western blot. Results: Specific IgE, which was detected in 15 of the 18 (83.3%) sera, indicated two nonoverlapping band patterns on the SDS–PAGE/Western blot: (1) pattern 1, present in 11 sera, consisted of three bands with estimated molecular weights (MWs) of 8, 7.5 and 7 kD, which are the MWs described for the allergens Gly m 2, Gly m 1A and Gly m 1B, respectively, and (2) pattern 2, present in 3 sera, consisted of a band with an estimated MW of 8.2–8.3 kD and four additional bands in a MW range of 25–36 kD. The remaining positive sera indicated very faint bands. Conclusions: This study confirms that soybean hulls contain three main allergens with MWs of 8, 7.5 and 7 kD, and indicates additional higher MW allergens, which selectively bind specific IgE of the sera that do not react with the three low MW components. This dichotomous and nonoverlapping pattern of allergen recognition has not been previously described.
- Sunyer J, Anto JM, Rodrigo MJ, Morell F: Case–control study of serum immunoglobulin–E antibodies reactive with soybean in epidemic asthma. Lancet 1989;1:179–182.
- Navarro C, Marquez M, Hernando L, Galvan F, Zapatero L, Caravaca F: Epidemic asthma in Cartagena, Spain, and its association with soybean sensitivity. Epidemiology 1993;4:76–78.
- Rodrigo MJ, Morell F, Helm RM, Swanson MC, Greife A, Anto JM, Sunyer J, Reed CE: Identification and partial characterization of the soybean–dust allergens involved in the Barcelona asthma epidemics. J Allergy Clin Immunol 1990;85:778–784.
Gonzalez R, Zapatero L, Caravaca F, Carreira J: Identification of soybean proteins responsible for respiratory allergies. Int Arch Allergy Appl Immunol 1991;95:53–57.
- Gonzalez R, Polo F, Zapatero L, Caravaca F, Carreira J: Purification and characterization of major inhalant allergens from soybean hulls. Clin Exp Allergy 1992;22:748–755.
- Codina R, Lockey RF, Fernandez–Caldas E, Rama R: Characterization of a soybean hull allergen responsible for the Barcelona asthma outbreaks. II. Purification and sequencing of the Gly m2 allergen. Clin Exp Allergy 1997; 27:424–430.
- Schagger H, von Jagow G: Tricine–sodium dodecyl sulfate–polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166: 368–397.
- Weber K, Osborn K: The reliability of molecular weight determinations by dodecyl sulfate–polyacrylamide gel electrophoresis. J Biol Chem 1969;244:4406–4412.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.